ASTCT/EBMT 6th International Conference on Relapse After Transplant and Cellular Therapy (HSCT²)



ASTCT and EBMT are proud to present the ASTCT/EBMT 6th International Conference on Relapse After Transplant and Cellular Therapy (HSCT²) taking place on November 10 - 11 in Los Angeles, California.

Relapse and disease progression are the leading causes of treatment failure for most hematologic malignancies treated with both allogeneic and autologous hematopoietic stem cell transplantation. During the last 5 years significant advances have been made in our understanding of the biology of relapse such as understanding the role of HLA loss in leukemia recurrence post-transplant. Since our 1st relapse meeting we now have three drugs approved to prevent disease recurrence post autologous transplant, and the role of FLT3 inhibitors and other TKIs to prevent relapse post allogeneic HCT is actively ongoing. Finally, the efficacy of CD 19 CAR T cell therapy for patients with disease relapsing after HCT has been firmly established for ALL and NHL.

Registration will open in Summer 2023. 

Agenda*

Day 1: Friday, November 10

Time Session
8:00 - 8:15 a.m.

Welcome and Introduction

Alan Wayne, MD; Children's Hospital Los Angeles/University of Southern California
Michael Bishop, MD; University of Chicago
Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center
Nicolaus Kroger, MD; University Hospital Hamburg
8:15 - 9:00 a.m. Keynote: Immune Metabolism
9:00 - 10:30 a.m.

Session I.A: Immune Reconstitution 
Session Chairs: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center; Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center

 

Speakers: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center; Jarrod Dudakov, PhD; Fred Hutchinson Cancer Center

 

Session I.B: Microbiome
Session Chairs: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center; Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center

Speakers: Jonathan Peled, MD; Memorial Sloan Kettering Cancer Center; Katherine King, MD, PhD; Baylor College of Medicine 
10:30 - 11:00 a.m. Break
11:00 - 11:45 a.m.

Session II: Mechanism of Relapse – Allo
Session Chairs: Leslie Kean, MD, PhD; Dana-Farber Cancer Institute/Boston’s Children Hospital; Luca Vago, MD, PhD; San Raffaele Scientific Institute

Speakers: Luca Vago, MD, PhD; San Raffaele Scientific Institute; Simone Minnie, PhD; Fred Hutchinson Cancer Center
11:45 - 1:00 p.m. Lunch
1:00 - 1:45 p.m. Session III: Mechanism of Relapse – Auto
Session Chairs: Anna Sureda, MD; Institut Català d'Oncologia-Hospital Duran i Reynals; Marcos de Lima, MD; Ohio State University

Speakers: Niccolo Bolli, MD, PhD; Universita degli Studi di Milano Statale; Lapo Alinari, MD, PhD; Ohio State University
1:45 - 2:15 p.m. Break
2:15 - 3:30 p.m. Session IV: Mechanism of Relapse – CAR Resistance 

Session Chairs: Nirali Shah, MD, MHSc, National Cancer Institute; Michael Bishop, MD; University of Chicago 

Speakers: Brian Sworder, MD, PhD; Stanford Health Care; Naomi Taylor, MD, PhD; National Cancer Institute; Corrine Summers, MD; Seattle Children's Hospital/Fred Hutchinson Cancer Center
3:30 - 4:15 p.m. Keynote Lecture: Synthetic CAR T Cells

Kole Roybal, PhD; University of California, San Francisco
4:15 - 5:15 p.m. Best Oral Abstracts
5:15 - 6:45 p.m. Welcome Reception 

Day 2: Saturday, November 11

Time Session
7:00 - 8:00 a.m. Product Theater
8:00 - 8:45 a.m. Keynote Lecture: Mechanisms of Relapse

John DiPersio, MD, PhD; Washington University, St. Louis
8:45 - 9:30 a.m. Session V: Mechanism of Relapse - Focus on T Cells 

Session Chairs: Robert Zeiser, MD; University of Freiburg; Shannon McCurdy, MD; University of Pennsylvania

Speakers: Petya Apostolova, MD; University of Basel, Switzerland; David Michonneau, MD, PhD; Hopital Saint-Louis
9:30 - 10:00 a.m. Break
10:00 - 11:15 a.m. Session VI: Minimal Residual Disease

Session Chairs: Charles Craddock, MD; University Hospitals of Birmingham; Brenda Sandmaier, MD; Fred Hutchinson Cancer Center

Speakers: Sylvie Freeman, DPhil, MBChB, MRCP, FRCPath, University of Birmingham; Michael Pusipher, MD; University of Utah; Graham Jackson, MD; Newcastle University
11:15 - 12:30 p.m. Session VII: Relapse Prevention

Session Chairs: David Porter, MD; University of Pennsylvania; Chiara Bonini, MD; San Raffaele Scientific Institute

Speakers: Victoria Potter, BSc, MBBS; Kings Private Hospital; Alexander Perl, MD; University of Pennsylvania; Robert Zeiser, MD; PhD; University of Freiburg
12:30 - 1:45 p.m. Lunch and Product Theater
1:45 - 3:15 p.m. Session VIII: Treatment of Relapse

Session Chairs: Rayne Rouce, MD;  Texas Children’s Hospital/Baylor College of Medicine;  Saar Gill, MD, PhD; University of Pennsylvania; Bronwen Shaw, MD, PhD; CIBMTR/Medical College of Wisconsin; Takanori Teshima, MD, PhD; Hokkaido University

Speakers: Saar Gill, MD, PhD; University of Pennsylvania; Leonido Luznik, MD; Johns Hopkins Medicine; Hugo Fernandez, MD; Moffit Cancer Center; Rayne Rouce, MD; Texas Children's Hospital/Baylor College of Medicine 
3:15 - 3:30 p.m. Concluding Remarks


*This agenda is current as of April 2023 but is subject to change.

Accreditation

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professions Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

Sponsorship

Please contact Angie Dahl for opportunities to sponsor or exhibit at the 6th Relapse After HCT Meeting.